"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves Pembrolizumab (Keytruda) for advanced ESCC

01 Aug 2019 7:40 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved pembrolizumab (Keytruda; Merck) for patients with recurrent, locally advanced or metastatic, squamous cell carcinoma of the esophagus (ESCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10), as determined by an FDA-approved test, with diesease progression after one or more prior lines of systemic therapy. Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software